Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.39 |
| ▸ | ATP4A | P20648 | 1/20 | 0.33 |
| ▸ | ATP4B | P51164 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | BRS3 | P32247 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azeloprazole SCHEMBL4336050 | 1.00 | WDR5 (0.40) | WDR5KMT2ASARM1ATP4AATP4B | |
| Azeloprazole SCHEMBL711094 | 1.00 | WDR5 (0.40) | WDR5KMT2ASARM1ATP4AATP4B | |
| Azeloprazole SCHEMBL710150 | 0.99 | KMT2A (0.40) | WDR5KMT2ASARM1ATP4AATP4B | |
| Azeloprazole SCHEMBL4333414 | 0.99 | KMT2A (0.40) | WDR5KMT2ASARM1ATP4AATP4B | |
| Azeloprazole SCHEMBL4333430 | 0.99 | KMT2A (0.40) | WDR5KMT2ASARM1ATP4AATP4B | |
| Azeloprazole SCHEMBL31312701 | 0.99 | KMT2A (0.40) | WDR5KMT2ASARM1ATP4AATP4B | |
| Azeloprazole SCHEMBL4492343 | 0.98 | WDR5 (0.40) | WDR5KMT2ASARM1ATP4AATP4B | |
| Azeloprazole SCHEMBL4336045 | 0.98 | WDR5 (0.40) | WDR5KMT2ASARM1ATP4AATP4B | |
| Azeloprazole SCHEMBL711093 | 0.98 | WDR5 (0.40) | WDR5KMT2ASARM1ATP4AATP4B | |
| Azeloprazole SCHEMBL4338561 | 0.98 | WDR5 (0.40) | WDR5KMT2ASARM1ATP4AATP4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090182149-A1 | SALT OF SULFINYLBENZIMIDAZOLE COMPOUND, AND CRYSTAL AND AMORPHOUS FORM THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-2077265-A1 | SALT OF SULFINYLBENZIMIDAZOLE COMPOUND, AND CRYSTAL AND AMORPHOUS FORM THEREOF | Eisai R&D Management Co., Ltd. (JP) | 2009-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182149-A1 | SALT OF SULFINYLBENZIMIDAZOLE COMPOUND, AND CRYSTAL AND AMORPHOUS FORM THEREOF | BRI3BP, SNRK, SRI | WDR5 1543/4885KMT2A 500/4885SARM1 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.